X

Trial Profile

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Relacorilant (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Registrational; Therapeutic Use
Acronyms RELIANT
Sponsors Corcept Therapeutics

Most Recent Events

04 Nov 2024 Results ( n=31) assessing antitumor activity of relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma published in the Oncologist.
07 Jun 2022 interim Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
11 May 2022 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com